- Benzinga•2 days ago
Below is a tool used by the Benzinga News Desk each trading day -- it's a look at everything happening in the market, in five minutes. Apply for daily AM access by clicking here or email email@example.com. ...
- Forbes•3 days ago
Biotech stocks have lagged this year. Should investors sell these stocks and invest in better performing sectors? Or, is this the best time in a long time to be buying biotech stocks now that they are relatively undervalued to other sectors? Todd Hagopian is buying because he believes the biotech industry is ripe for acquisitions as large, cash-flow rich drug companies look for promising new products.
After hours: 62.630.00 (0.00%) as of 5:35 PM EDT
|Bid||62.20 x 300|
|Ask||63.17 x 800|
|52wk Range||26.41 - 63.35|
|Day's Range||62.50 - 63.35|
|Avg Vol (3m)||2,760,515|
As of 4:00 PM EDT. Market closed.